FDA warned Wizcure Pharmaa about serious manufacturing and data-integrity failures in sterile OTC drugs.
What happened
FDA inspected the Bhiwadi, Rajasthan facility from December 3 to 10, 2025. Investigators found laboratory records did not include complete original data: microbial plates showing growth were discarded and replaced with no-growth plates, and required environmental and personnel monitoring samples were missed. They also found the aseptic filling line lacked a physical barrier, product-contact equipment was not sterilized, equipment was rusty, and media fills and airflow studies were inadequate.
What FDA found
Laboratory records did not include complete original data; microbial plates with visible growth were thrown away and replaced with plates showing no growth, and required monitoring samples were missed.
21 CFR 211.194(a)The aseptic filling line had no physical barrier between the ISO 5 filling zone and the ISO 7 room, product-contact equipment was not sterilized, and the room lacked adequate space for people and materials.
21 CFR 211.42(c)(10)Media fills did not represent commercial aseptic operations, batch records did not document all personnel and interventions, smoke studies were not done under dynamic conditions, and aseptic operator practices deviated.
21 CFR 211.113(b)The filling line and air filters above it had rust or stains, and equipment was not adequately cleaned and maintained for sterile manufacturing.
21 CFR 211.67(a)
What FDA wants
FDA asks Wizcure to provide independent assessments and detailed remediation and CAPA plans covering laboratory data integrity, aseptic facilities and contamination controls, environmental monitoring, media fills, airflow, equipment, the quality unit, and related systems. FDA also asks the firm to clarify whether it will resume U.S. manufacturing and to notify FDA before resuming; the letter does not state a response deadline.
Who should pay attention
- companies that buy or distribute Wizcure sterile OTC drugs
- sterile drug manufacturers and contract manufacturers that rely on microbial monitoring
- quality and regulatory teams responsible for U.S. marketed sterile products
This is a summary. Read the original letter on fda.gov.